BioCentury
ARTICLE | Financial News

Non-coding RNA company Twentyeight-Seven debuts with $65M

September 7, 2018 5:46 PM UTC

Twentyeight-Seven Therapeutics Inc. (Cambridge, Mass.) raised $65 million on Sept. 6 in a series A round co-led by MPM Capital and Novartis Venture Fund. Johnson & Johnson Innovation-JJDC Inc., Vertex Ventures HC, Longwood Fund and Astellas Venture Management also participated in the round. MPM and Astellas were investors in Twentyeight-Seven's undisclosed seed round.

The biotech is focusing on modulating microRNAs. Non-coding RNAs such as miRNAs have been drawing increasing attention from drug developers due to the numbers of molecules being uncovered with apparent translational potential. Most work has centered on understanding how non-coding RNAs regulate gene expression by modulating mRNA degradation or translation (see "RNA Party")...